Apple’s strategy for its Apple Music service may offer an apt analogy to help us reframe the therapy research and development enterprise.
Drug combinations make sense both from the science and from the business perspective.
Like systematic drug repurposing, big data analytics recognises that there is value in “knowing what we know”. Both can lead to innovation and both can play a significant role in shaping the healthcare environment of the future.
Recent Biovista work that shows it is possible to predict risk factors reliably, clears the way to systematic use of this capability by the healthcare industry.
Andreas Persidis, CEO In a recent post at the Drug Repositioning discussion group of LinkedIn, John Waslif alerted the community to an interesting article by Michael Kinch titled “The Process by which Drugs are Discovered and Developed will be Fundamentally Different in the Future”. I guess no one will argue with such a statement. What … Read More